leisure time -WSS

leisure time

author：hotspot 2025-10-01 22:57:18 - browse：268

glum Benjamin — health insurance coverage from STAT — Adobe

Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences.

Scion was started by former Apple Tree Partners colleagues Sam Hall and Aaron Kantoff, along with Tadd Wessel, managing partner of the health care private equity firm Petrichor. They raised $310 million for its first fund, blowing past their original $250 million target.

They’re planning on taking a different tack with biotech venture capital. For starters, Scion plans to work on a significantly longer timeframe. Most firms in existence today write checks, help investments grow, and find a way to recoup their money in a 10-year timeframe. Scion is doubling that, setting a 20-year plan for its first fund.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： As JPM 2024 winds down, some health tech firms project optimism

Wikipedia

WSS

Study on Amgen’s bispecific immunotherapy produces positive data

ADCs take center stage as promising cancer treatments

STAT Summit: Meghan O’Rourke on making chronic illness visible

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

DeSantis can now import cheaper drugs. But will Biden get credit?

Roche drug slashes death risk in early

Wikipedia

leisure time

focus

Psychedelics group wrestles with new pharma identity

Caregivers of transplant patients call for more support, training

Wildfire smoke exposes gaps in outdoor worker protections

J&J lung cancer data amount to new salvo against AstraZeneca

Walensky prepares to leave CDC — and Congress — behind

STAT Summit: Meghan O’Rourke on making chronic illness visible

Bright Health sells Medicare Advantage business to Molina

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Heart attack and stroke risk calculators need revising

Designating disabled people as health disparity population is crucial

explore

STAT Readout Newsletter: Biotech news today

J&J lung cancer data amount to new salvo against AstraZeneca

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Doulas covered by Medicaid under New York's new plan

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

STAT Readout: Friday, Oct. 20 biotech updates

entertainment

focus

Wikipedia

explore